<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795182</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111_BGB-A317_Study_001</org_study_id>
    <nct_id>NCT02795182</nct_id>
  </id_info>
  <brief_title>BGB-3111 in Combination With BGB-A317 in Subjects With B-cell Malignancies</brief_title>
  <official_title>A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 With BGB-A317 in Subjects With B-Cell Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with
      BGB-A317 in subjects with B-cell lymphoid malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From first dose to 28 days after last dose of BGB-3111 or BGB-A317</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the time of the last measureable concentration (AUClast)</measure>
    <time_frame>the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to infinity time (AUC0-infinity)</measure>
    <time_frame>the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BTK inhibition activity of BGB-3111 by measurement of free BTK</measure>
    <time_frame>the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Every 12 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>BGB-3111 and BGB-A317</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the dose -escalation part, the dose levels and regimens will be evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-3111</intervention_name>
    <arm_group_label>BGB-3111 and BGB-A317</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-A317</intervention_name>
    <arm_group_label>BGB-3111 and BGB-A317</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 18 years, able and willing to provide written informed consent and to comply
             with the study protocol.

          -  Laboratory parameters as specified below:

               -  Hematologic: platelet count &gt; 50 x 10e9/L; absolute neutrophil count &gt; 1.0 x109
                  cells/L;

               -  Hepatic: total Bilirubin ≤ 1.5 times the upper limit of normal (ULN) ; and
                  aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ≤ 3x ULN

               -  Renal: creatinine clearance ≥ 30 mL/min ; subjects requiring hemodialysis will be
                  excluded.

          -  Anticipated survival of at least 4 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

          -  Female subjects of childbearing potential and non-sterile males must practice at least
             one of the following methods of birth control with partner(s) throughout the study and
             for ≥ 3 months after discontinuing study drugs: total abstinence from sexual
             intercourse, double-barrier contraception, intrauterine device or hormonal
             contraceptive initiated at least 3 months prior to first dose of study drugs.

          -  Male subjects must not donate sperm from initial study drug administration, until 180
             days after drug discontinuation.

        Exclusion Criteria:

          -  Known, active, central nervous system lymphoma or leukemia

          -  Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura

          -  History of stroke or cerebral hemorrhage within 6 months of enrollment

          -  History of significant cardiovascular disease, defined as:

               -  Congestive heart failure greater than New York Heart Association (NYHA) class II
                  according to the NYHA functional classification

               -  Unstable angina or myocardial infarction with 6 months of enrollment

          -  Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of
             breath, congestive obstructive pulmonary disease)

          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy

          -  Prior Bruton's tyrosine kinase (BTK) inhibitor or anti- programmed cell death-1
             (PD-1)/anti-Programmed Death Ligand-1 (PD-L1) treatment.

          -  History of interstitial lung disease or non-infectious pneumonitis except for those
             induced by radiation therapies

          -  Vaccination with a live vaccine within 28 days of the initiation of treatment.

          -  Participated in any investigational drug study within 28 days or not recovered from
             toxicity of any prior chemotherapy to grade ≤ 1.

          -  Major surgery in the past 4 weeks

          -  Active and symptomatic fungal, bacterial and/or viral infection including evidence of
             infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus
             type 1 seropositive status

          -  Inability to comply with study procedures

          -  Pregnant or nursing women

          -  Men or women of childbearing potential who refuse to use an adequate measure of
             contraception unless they have past medical history of surgical sterilization.

          -  Any illness or condition that in the opinion of the investigator may affect safety of
             treatment or evaluation of any study's endpoints
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Hedrick, MD</last_name>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Hospital</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>November 23, 2017</last_update_submitted>
  <last_update_submitted_qc>November 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

